Support us by your subscription
You have reached your monthly allowance of 1 free premium articles from The Pharmaceutical Journal and Clinical Pharmacist. Sign in or register for free to access 2 more articles. Subscribe for full access to The Pharmaceutical Journal and Clinical Pharmacist and CPD modules.
Note: CPD articles and modules are only available to full subscribers and members of the Royal Pharmaceutical Society. You can subscribe for as little as £5 a week.
Use the code0516EMSB2DP for 20% discount on our annual digital subscriptions.
Researchers dispute the therapeutic mode of action of a ketamine metabolite
A study in Nature contradicts a previous report on synaptic NMDAR inhibition by a ketamine metabolite, a potential antidepressant.
Are you already a registered user or a member of the Royal Pharmaceutical Society?
Sign in hereInstitutional users can view premium content by verifying themselves with one of the following options:
myAthens ShibbolethSubscribe to and support The Pharmaceutical Journal and Clinical Pharmacist
Subscribe today for as little as £5
Subscribe for as little as £5, to gain full, unlimited access to the ultimate source of information and news on pharmacy and pharmaceutical sciences.
Subscribe todayRegister for free for more access
Alternatively, register for free to the site for access to an extra 2 premium articles for free.
Register now.Need an institutional subscription?
Please contact The Pharmaceutical Journal directly, so we can provide you with detailed information about our institutional and corporate offerings.
Tel: +44 (0)20 7572 2221
Email: pjsubscription@rpharms.com
Or join the RPS for full access
As a pharmacist or pharmaceutical scientist, join the Royal Pharmaceutical Society and gain full access to pharmaceutical-journal.com
Membership is free for pharmacy students.
If you are not registered as a pharmacist in Great Britain or practise overseas, you may still be able to join the RPS as an associate member.
Become a member